Back to Search
Start Over
Effects of Patiromer and Sodium Zirconium Cyclosilicate on Blood Pressure in Rats with Chronic Kidney Disease
- Source :
- Journal of Cardiovascular Pharmacology and Therapeutics, Vol 29 (2024)
- Publication Year :
- 2024
- Publisher :
- SAGE Publishing, 2024.
-
Abstract
- Background Potassium-binders patiromer and sodium zirconium cyclosilicate (SZC) are approved to treat hyperkalaemia, which is frequently observed in chronic kidney disease (CKD). Elevated blood pressure (BP) is common in CKD, due in part to impaired sodium excretion. The effect of patiromer, which exchanges calcium for potassium and SZC, which exchanges sodium or hydrogen for potassium, on BP was assessed in a CKD rat model. Methods Thirty-six Sprague Dawley rats with 5/6 nephrectomy were randomised to three groups (n = 12/group) to receive 4 g/kg/day patiromer or SZC, or vehicle treatment, for 8 weeks. BP was determined by radiotelemetry and urinary protein and electrolytes were measured. Results At Week 8, systolic BP (sBP) increased in all groups; however, patiromer led to a lower mean (standard deviation) sBP than vehicle or SZC (141 [2.9] vs 158 [5.2] or 162 [6.1] mm Hg, respectively, both p
Details
- Language :
- English
- ISSN :
- 19404034 and 10742484
- Volume :
- 29
- Database :
- Directory of Open Access Journals
- Journal :
- Journal of Cardiovascular Pharmacology and Therapeutics
- Publication Type :
- Academic Journal
- Accession number :
- edsdoj.9a0a86994e874387a3da7d7e544bc59d
- Document Type :
- article
- Full Text :
- https://doi.org/10.1177/10742484241227580